Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.
You may also be interested in...
FDA Safety Panel: All MRI Gadolinium Contrast Agents Are Not Created Equal
GE Healthcare's gadolinium MRI imaging contrast agent Omniscan stands to lose following a safety review by a joint FDA advisory committee, while rival products with a proven safety advantage could gain from the expert panel's recommendations
FDA Safety Panel: All MRI Gadolinium Contrast Agents Are Not Created Equal
GE Healthcare's gadolinium MRI imaging contrast agent Omniscan stands to lose following a safety review by a joint FDA advisory committee, while rival products with a proven safety advantage could gain from the expert panel's recommendations
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.